NATURE’S SUNSHINE PRODUCTS, INC. Capital Expenditures Incurred but Not yet Paid
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Capital Expenditures Incurred but Not yet Paid of $758.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-10
- NATURE’S SUNSHINE PRODUCTS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $758.00K, a 277.11% increase from fiscal 2024.
- NATURE’S SUNSHINE PRODUCTS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $201.00K, a 65.93% decline from fiscal 2023.
- NATURE’S SUNSHINE PRODUCTS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $590.00K, a 57.33% increase from fiscal 2022.
- NATURE’S SUNSHINE PRODUCTS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $375.00K, a 13.64% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|
| 2025-12-31 | $758.00K 10-K · filed 2026-03-10 |
| 2024-12-31 | $201.00K 10-K · filed 2026-03-10 |
| 2023-12-31 | $590.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $375.00K 10-K · filed 2024-03-12 |
| 2021-12-31 | $330.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $85.00K 10-K · filed 2022-03-08 |
| 2019-12-31 | $194.00K 10-K · filed 2021-03-10 |
| 2018-12-31 | $32.00K 10-K · filed 2020-03-11 |
| 2017-12-31 | $63.00K 10-K · filed 2019-03-08 |
| 2016-12-31 | $178.00K 10-K · filed 2019-03-08 |
| 2015-12-31 | $1.08M 10-K · filed 2018-03-16 |
| 2014-12-31 | $780.00K 10-K · filed 2017-03-14 |
| 2013-12-31 | $155.00K 10-K · filed 2016-03-14 |
| 2012-12-31 | $169.00K 10-K · filed 2015-03-13 |
| 2011-12-31 | $19.00K 10-K · filed 2014-03-17 |
| 2010-12-31 | $196.00K 10-K · filed 2013-03-07 |
| 2009-12-31 | $114.00K 10-K · filed 2012-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |